Table 1. Association between FOXF2 mRNA levels in primary breast cancer tissues and clinicopathological variables.

Variables	Cases	Median levels of FOXF2 (1×10−4)	Rank sum tests		FOXF2 mRNA level		Chi-square test
			Z/χ2	P	Low (%)	High (%)	χ2	P
Age (years)
≤45	78	3.88 (0.13–28.62)	2.355	0.308	27 (34.6)	51(65.4)	1.700	0.427
45–55	130	3.45 (0.16–34.62 )			52 (40.0)	78 (60.0)
>55	97	3.40 (0.15–18.04 )			43 (44.3)	54 (55.7)
Menopausal status
Premenopausal	150	3.82 (0.13–28.62 )	−1.823	0.068	55 (36.7)	95 (63.3)	1.506	0.220
Postmenopausal	149	3.41 (0.15–34.62 )			65 (43.6)	84 (56.4)
Missing	6	3.44 (2.50–4.95 )			2 (33.3)	4 (66.7)
Tumor size (cm)
T1 (<2)	89	4.51 (0.15–34.62 )	7.302	0.026	24 (27.0)	65 (73.0)	9.744	0.008
T2 (2–5)	198	3.40 (0.16–28.62 )			88 (44.4)	110 (55.6)
T3 (>5)	18	2.39 (0.13–9.84)			10 (55.6)	8 (44.4)
Clinical stage
I	24	4.65 (0.77–34.62 )	5.867	0.053	6 (25.0)	18 (75.0)	8.832	0.012
II	228	3.72 (0.15–28.62			86 (37.7)	142 (62.3)
III	53	2.50 (0.13–13.04)			30 (56.6)	23 (43.3)
LN involvement
Negative 0	123	4.06 (0.16–34.62 )	8.288	0.040	41 (33.3)	82 (66.7)	7.584	0.055
Positive 1–3	105	3.56 (0.16–20.28 )			41 (39.0)	64 (61.0)
4–9	40	3.26 (0.15–25.68 )			19 (47.5)	21 (52.5)
≥10	37	2.43 (0.13–13.89)			21 (56.8)	16 (43.2)
Histological grade
I	5	5.86 (0.39–9.51 )	0.198	0.906	2 (40.0)	3 (60.0)	0.007	0.996
II	226	3.66 (0.13–34.62 )			88 (38.9)	138 (61.1)
III	43	3.66 (0.48–20.28 )			17 (39.5)	26 (60.5)
Missing	31
Molecular subtypes
Luminal A	138	3.85 (0.39–34.62 )	5.010	0.171	48 (34.8)	90 (65.2)	5.317	0.150
Luminal B	37	3.66 (0.16–25.68 )			14 (37.8)	23 (62.2)
HER2-positive	52	2.74 (0.13–14.77 )			27 (51.9)	25 (48.1)
Triple-negative	39	3.06 (0.15–28.62 )			18 (46.2)	21 (53.8)
Missing	39

Note: “Missing” indicates the number of cases for which the corresponding information was not available.